title: Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment.
abstract: A 27-year-old Caucasian female with hepatitis C virus (HCV) infection treated with interferon (IFN) who developed severe autoimmune hepatitis (AIH) is described. The infecting viral strain was of genotype Ib and the pre-treatment HCV viral load was at a high level. The patient was treated with pegylated IFN-alpha 2b and ribavirin, and her HCV-RNA became negative at wk 12, but after that she developed fulminant hepatic failure. The patient recovered after steroid pulse therapy consisting of methylprednisolone 1000 mg/d for three days which was administered twice. A needle liver biopsy revealed the typical pathological findings of AIH.
authors: Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai City 980-8574, Japan.
authors: Takayuki
authors: T
authors: Kogure
authors: Yoshiyuki
authors: Y
authors: Ueno
authors: Koji
authors: K
authors: Fukushima
authors: Futoshi
authors: F
authors: Nagasaki
authors: Jun
authors: J
authors: Inoue
authors: Eiji
authors: E
authors: Kakazu
authors: Yasunori
authors: Y
authors: Matsuda
authors: Osamu
authors: O
authors: Kido
authors: Yu
authors: Y
authors: Nakagome
authors: Osamu
authors: O
authors: Kimura
authors: Noriyuki
authors: N
authors: Obara
authors: Yuta
authors: Y
authors: Wakui
authors: Takao
authors: T
authors: Iwasaki
authors: Tooru
authors: T
authors: Shimosegawa
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D019693:Hepatitis, Autoimmune / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000175:diagnosis; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b
references: Gastroenterology. 1995 Jun;108(6):1770-7
references: 7768382
references: World J Gastroenterol. 2006 Jul 14;12 (26):4253-5
references: 16830387
references: Hepatology. 2004 Apr;39(4):1147-71
references: 15057920
references: Gastroenterology. 2001 May;120(6):1485-501
references: 11313320
references: Gastroenterology. 1992 Apr;102(4 Pt 1):1406-8
references: 1551549
references: Eur J Immunol. 1993 May;23(5):1105-11
references: 7682958
references: Hepatology. 1995 Nov;22(5):1374-8
references: 7590650
references: Am J Hematol. 2003 Mar;72(3):170-6
references: 12605388
references: Transplantation. 2006 Feb 15;81(3):488-90
references: 16477242
references: Autoimmunity. 2003 Dec;36(8):519-23
references: 14984029
references: Ann Intern Med. 1992 Jan 1;116(1):51-3
references: 1727095
references: World J Gastroenterol. 2004 Jan;10(1):12-6
references: 14695760
references: Liver Transpl. 2006 May;12 (5):827-30
references: 16628699
references: J Exp Med. 1999 Jul 19;190(2):169-76
references: 10432280